AUS
NZ
UK
CA
USA
IND
Highlights
- Numinus Wellness shares have seen a significant decline recently.
- The company's revenue growth has been impressive compared to the industry.
- Market expectations for future growth remain uncertain.
Numinus Wellness Inc. (TSX:NUMI) shares have retraced considerably in the last month, reversing much of their recent solid performance. This recent drop completes a challenging twelve months for those with the stock, who have experienced substantial losses during that time.
Price-to-Sales Ratio and Market Expectations
Despite the heavy fall in price, Numinus Wellness' price-to-sales (P/S) ratio of 0.6x is still close to the median P/S ratio for the Pharmaceuticals industry in Canada, which is around 0.8x. While this might not raise any eyebrows, if the P/S ratio is not justified, market participants could be missing out on potential opportunities or ignoring looming disappointments.
Recent Revenue Performance
Recent times have been advantageous for Numinus Wellness as its revenues have been rising faster than most other companies. Perhaps the market is expecting this level of performance to taper off, keeping the P/S from soaring. If the company manages to stay the course, then those with the stock should see a share price that matches its revenue figures.
Revenue Growth Trends
Looking back, the company grew revenue impressively last year. The latest three-year period has also seen an incredible overall rise in revenue, aided by its strong short-term performance. Accordingly, those with the stock would have been pleased with those medium-term rates of revenue growth.
Future Revenue Expectations
Shifting to the future, estimates from the coverage suggest revenue should grow significantly over the next three years. Meanwhile, the rest of the industry is forecast to expand at a noticeably lower rate.
Market Sentiment and P/S Ratio
In light of this, it's curious that Numinus Wellness' P/S sits in line with the majority of other companies. It may be that most market participants aren't convinced the company can achieve future growth expectations. Numinus Wellness' plummeting stock price has brought its P/S back to a similar region as the rest of the industry. While the price-to-sales ratio shouldn't be the defining factor in evaluating a stock, it's a capable barometer of revenue expectations.
We've established that Numinus Wellness currently trades on a lower than expected P/S since its forecasted revenue growth is higher than the wider industry. Perhaps uncertainty in the revenue forecasts is what's keeping the P/S ratio consistent with the rest of the industry. It appears some are indeed anticipating revenue instability, because these conditions should normally provide a boost to the share price.
